Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • dexpramipexole

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    Biogen expands portfolio in deal with Alcyone Therapeutics

    The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

    An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

    Biogen Idec building

    Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

    Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

    Biogen Idec building

    Biogen to boost US manufacturing footprint with $2bn North Carolina investment

    The commitment is aimed at advancing the company's late-stage clinical pipeline

    Biogen Idec building

    Biogen initiates phase 3 study of felzartamab in kidney disease patients

    Approximately 36,000 people in the US are affected by primary membranous nephropathy

    Biogen Idec building

    Biogen and City Therapeutics to develop RNAi therapies in deal worth over $1bn

    The partners will focus on a target that mediates key central nervous system diseases

    - PMLiVE

    Eli Lilly and Alchemab Therapeutics enter ALS agreement worth up to $415m

    The deal follows the companies’ earlier partnership to advance candidates for the neurodegenerative disease

    Biogen Idec building

    Biogen’s Skyclarys granted MHRA approval for rare movement disorder Friedreich’s ataxia

    The neurodegenerative disease affects at least one in every 50,000 people in the UK

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

    The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

    Biogen Idec building

    Biogen unveils plans for new global headquarters and R&D hub in US

    The company is expecting to relocate its Cambridge-based employees to the new site in 2028

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links